

SUPPLEMENTARY MATERIAL

Supplemental Table S1. Overview of comparative studies on thromboprophylaxis in Fontan reported in this review

Author, year	Study type	Era	Cohort size, Fontan-type	Age	FU time	Antithrombotics (n)	TE, n (%)	MB, n (%)	Efficacy (TE)	Safety (MB)	
<i>Alsaied</i> 2015	Meta-analysis	1973-2009	1200	3.4-8.5	7.1	None (199)	37 (18.6)	-	ASA vs VKA	N/A	
			APC, LT, ECC			ASA (465)	40 (8.6)	-	OR 0.9 (NS)		
						VKA (536)	48 (9.0)	2 (0.4)			
<i>Monagle</i> 2011	RCT	1998-2003	111	4.8	2.0	ASA (57)	12 (21.1)	0	VKA vs ASA	NS	
			LT, ECC			VKA (54)	13 (24.1)	1 (1.9)	HR 1.4 (NS)		
<i>Pessotti</i> 2014	RCT	2008-2011	30	5.3	2.0	ASA (15)	7 (46.7)	0	NS	N/A	
			ECC			VKA (15)	3 (20)	0			
<i>McCrinkle</i> 2021	RCT	2013-2019	112	4.1	1.0	ASA (34)	3 (8.8)	0	NS	NS	
							Rivarox (66)	1 (1.5)	1 (1.5)		
<i>Al-Jazairi</i> 2019	Observational	1985-2010	431	2.4	13.6	None (29)	-	-	NS	NS	
			APC, LT, ECC			ASA (36)	0.6%/yr	0.3%/yr			
						VKA (366)	0.8%/yr	0.4%/yr			
<i>Small</i> 2018	Observational	2004-2017	26	25.9	2.8	ASA (13)	6 (46.1)	1 (7.7)	NS	NS	
			APC			VKA (13)	1 (7.7)	3 (23.1)			
<i>Iyengar</i> 2016	Observational	1997-2010	475	4.8	7.0	None (17)	0	-	VKA vs ASA	N/A	
			ECC			ASA (157)	6 (3.8)	-	HR 1.3 (NS)		
						VKA (301)	12 (4)	11 (3.7)			
<i>Kawamatsu</i> 2021	Observational	N/A	102	27	7.9	None (5)	2 (40)	0	NOAC vs VKA:	NOAC vs VKA:	
							NOAC (36)	0	1 (2.8)	P = 0.025	HR 0.3 (NS)
							VKA (41)	5 (12.2)	6 (14.6)		
							ASA (43)	3 (7)	3 (7)		
							Combi (14)	0	8 (57.1)		
<i>Ankola</i> 2021	Observational	2006-2016	192	3.3	30 days	None (14)	11 (78.6)	-	VKA vs ASA:	N/A	
							ASA (103)	5 (4.9)	-	OR 1.1 (NS)	
							VKA (52)	2 (3.8)	-		
							Heparin (20)	1 (5)	-		

TE = thromboembolic event; MB = major bleeding; VKA = vitamin K antagonist; ASA = acetylsalicylic acid; ATP = antiplatelets; NS = not statistically significant; N/A = not available